 |
 Video: What is a Stock Split?
|
|
|
| Cue Biopharma is a clinical-stage biopharmaceutical company. Co.'s proprietary Immuno-Selective Targeting and Alteration of T Cells (Immuno-STAT™) platform, enable Co. to restore health while avoiding the side effects of immune activation in the case of cancer and immune suppression in the case of autoimmune disease. Co. focused its internal resources on drug product candidates in its CUE-100 series of Immuno-STATs. The CUE-100 series uses the selectivity of the T cell receptor combined with rationally engineered interleukin 2 in context of the core Immuno-STAT framework for selective activation of targeted tumor-specific T cells to potentially address a range of cancers. According to our Cue Biopharma stock split history records, Cue Biopharma has had 0 splits. | |
|
Cue Biopharma (CUE) has 0 splits in our Cue Biopharma stock split history database.
Looking at the Cue Biopharma stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Cue Biopharma shares, starting with a $10,000 purchase of CUE, presented on a split-history-adjusted basis factoring in the complete Cue Biopharma stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
01/03/2018 |
|
| End date: |
04/26/2024 |
|
| Start price/share: |
$12.75 |
|
| End price/share: |
$1.36 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-89.29% |
|
| Average Annual Total Return: |
-29.81% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$1,070.63 |
|
| Years: |
6.31 |
|
|
|
|
|
